Edgar Filing: RODMAN & RENSHAW CAPITAL GROUP, INC. - Form 8-K

RODMAN & RENSHAW CAPITAL GROUP, INC. Form 8-K

October 27, 2009

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

\_\_\_\_\_

### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 27, 2009

# RODMAN & RENSHAW CAPITAL GROUP, INC. (Exact name of Registrant as specified in its charter)

Delaware 001-33737 84-1374481 (State or other jurisdiction of incorporation) File Number) Identification No.)

1251 Avenue of the Americas, New York, New York (Address Of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code (212) 356-0500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: RODMAN & RENSHAW CAPITAL GROUP, INC. - Form 8-K

#### Item 8.01. Other Events.

On October 27, 2009, Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM) issued the press release attached hereto as Exhibit 99.1, announcing the sale by its affiliate, Aceras BioMedical LLC, of Huxley Pharmaceuticals Inc., an Aceras portfolio company, to BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).

### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.

Description

99.1

Press release dated October 27, 2009.

\*\*\*\*

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Rodman & Renshaw Capital Group, Inc.

Dated: October 27, 2009

By: <u>/s/ David J. Horin</u>
David J. Horin
Chief Financial Officer